The Marcus
MCSNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $27.20 Prior regular-session close from the quote source.
- $26.74–$27.40 Regular-session low and high so far today.
- 153.8K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Feb 25 projected Projected for 2027-02-25 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $14.63–$32.42 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own MCS if Marcus Corp is an asset-heavy, cash-generative theatre company whose durable value depends on steady box-office and concession cash flows, a conservative balance sheet that lets management return cash to shareholders, and the absence of.
MCS price history
Loading recent earnings…
Investment thesis
What must happen next
Marcus' core operations consistently generate meaningful operating cash flow that funds dividends, capex and shareholder returns; that operating cash flow is the company's primary economic moat/driver.StrengtheningMateriality: High
operating_cash_flow: 93,209,000 (FY2022). If operating cash flow stays robust, management can return cash and sustain the business without risky leverage or dilutive capital raises; if it falls, liquidity and shareholder returns are threatened.
Watch: A new pandemic or region-wide public-health restrictions causing theatre closures/revenue collapse.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_cash_flow: 93,209,000 (FY2022).
Open source ↗Individual theatre cash flows are impairment-sensitive; when local property-level cash flows weaken management will record impairments that reduce assets and compress future operating returns.StrengtheningMateriality: High
MD&A disclosure: Company recorded an impairment loss of $5.2 million during the year ended December 31, 2025. Repeated or large impairments would directly shrink the asset base, reduce reported earnings and signal that theatre economics cannot sustain the asset carrying values — this is a leading indicator of permanent value loss.
Watch: A multi-year soft box-office environment (e.g., studios shift top titles to streaming or reduce theatrical windows) that lowers forecasted per-theatre cash flows.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
MD&A disclosure: Company recorded an impairment loss of $5.2 million during the year ended December 31, 2025.
Open source ↗Marcus' asset-heavy balance sheet and ~ $457M equity base give management the capacity to fund dividends, capex and opportunistic buybacks or acquisitions without taking aggressive new leverage, supporting returns if cash flow persists.HoldingMateriality: Medium
equity: 457,378,000 (instant 2025-12-31). A conservative balance sheet combined with stable cash flow allows shareholder-friendly capital allocation; if cash flow weakens the balance sheet cushion shrinks and capital returns will likely be reduced.
Watch: Large one-time acquisition or major capex program funded with debt that meaningfully increases liabilities.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
equity: 457,378,000 (instant 2025-12-31).
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Marcus' core operations consistently generate meaningful operating cash flow that funds dividends, capex and shareholder returns; that operating cash flow is the company's primary economic moat/driver. If operating cash flow stays robust, management can return cash and sustain the business without risky leverage or dilutive capital raises; if it falls, liquidity and shareholder returns are threatened.
Individual theatre cash flows are impairment-sensitive; when local property-level cash flows weaken management will record impairments that reduce assets and compress future operating returns. Repeated or large impairments would directly shrink the asset base, reduce reported earnings and signal that theatre economics cannot sustain the asset carrying values — this is a leading indicator of permanent value loss.
Marcus' asset-heavy balance sheet and ~ $457M equity base give management the capacity to fund dividends, capex and opportunistic buybacks or acquisitions without taking aggressive new leverage, supporting returns if cash flow persists. A conservative balance sheet combined with stable cash flow allows shareholder-friendly capital allocation; if cash flow weakens the balance sheet cushion shrinks and capital returns will likely be reduced.
All standing thesis claims
Original report summary
Marcus Corp is an asset-heavy, cash-generative theatre company whose durable value depends on steady box-office and concession cash flows, a conservative balance sheet that lets management return cash to shareholders, and the absence of.
Bull case and bear case
Bull case and bear case for Marcus
Where the evidence on Marcus stands: Holding on the latest evidence (Nov 7, 2026). Of its 3 thesis points, 2 strengthening and 1 holding.
Bull case: what the evidence supports
Marcus' core operations consistently generate meaningful operating cash flow that funds dividends, capex and shareholder returns; that operating cash flow is the company's primary economic moat/driver.
Individual theatre cash flows are impairment-sensitive; when local property-level cash flows weaken management will record impairments that reduce assets and compress future operating returns.
Marcus' asset-heavy balance sheet and ~ $457M equity base give management the capacity to fund dividends, capex and opportunistic buybacks or acquisitions without taking aggressive new leverage, supporting returns if cash flow persists.
Bear case: what would count against it
A new pandemic or region-wide public-health restrictions causing theatre closures/revenue collapse.
A multi-year soft box-office environment (e.g., studios shift top titles to streaming or reduce theatrical windows) that lowers forecasted per-theatre cash flows.
Large one-time acquisition or major capex program funded with debt that meaningfully increases liabilities.
Thesis-Break Engine
Thesis-break watch · Marcus
Loading the break-condition record for Marcus.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Marcus filed an SEC 8-K on 2026-10-29: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Marcus filed an SEC 8-K on 2026-07-30: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
Marcus filed an SEC 8-K on 2026-04-30: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A new pandemic or region-wide public-health restrictions causing theatre closures/revenue collapse.
- A multi-year soft box-office environment (e.g., studios shift top titles to streaming or reduce theatrical windows) that lowers forecasted per-theatre cash flows.
- Large one-time acquisition or major capex program funded with debt that meaningfully increases liabilities.
MCS news
Loading headlines…
Financial statements
MCS income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
MCS: quick answers
- When does Marcus (MCS) report earnings next?
- Marcus's next results are projected for February 25, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on October 29, 2026. Earnings calendar
- What is MCS's short interest?
- As of October 30, 2026, 1.2M MCS shares were sold short, 4.95% of its shares outstanding, up 11.3% from the count before. At the stock's average daily volume that is 5.8 days to cover. FINRA publishes the count twice a month. MCS short interest history
- Have members of Congress traded MCS?
- 1 trade in MCS has been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed MCS trade
